Abstract
Human epidermal growth factor 2 (HER2 or ErbB2) mutations in lung cancer are oncogenic drivers similar to epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancers. Until recently, ErbB2-mutant lung cancers have generally been resistant to various targeted agents. However, a new wave of ErbB2-targeting drugs has shown promise for this subset. We highlight a case of a patient with an ErbB2-mutant lung cancer with an exon 20 YVMA insertion who had a good response to poziotinib and review the current literature on the methods of testing for ErbB2 mutations and the efficacy of various known and emerging targeted agents.
Original language | English (US) |
---|---|
Article number | 27 |
Journal | Precision Cancer Medicine |
Volume | 2 |
Issue number | November |
DOIs | |
State | Published - Nov 2019 |
Keywords
- ErbB2 mutations
- Exon 20 YVMA insertion
- Non-small cell lung cancer (NSCLC)
- Poziotinib
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Oncology(nursing)
- Pharmacology (medical)
- Surgery
- Anesthesiology and Pain Medicine